Results 141 to 150 of about 2,742,410 (287)

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Pharmacalogical management of obesity

, 2015
Obesity is now an epidemic. The whole world which includes the developed and developing countries is grappling with the adverse effects of obesity. The creation of anti- obesity drugs has been a gigantic stride in the combat against obesity.
Mbamali, Afoamakachukwu Adaeze
core  

Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy. [PDF]

J Clin Med
Belančić A, Skroče K, Gkrinia EMM, Marinović Glavić M, Kwok MK.   +4 more
europepmc   +1 more source

Clock Genes Regulate Ca2+ Signaling and Mitochondrial Bioenergetics to Inhibit Sjögren Disease

Arthritis &Rheumatology, EarlyView.
Objective Although Ca2+ signaling and metabolism have been identified as key determinants for the development of Sjögren disease (SjD), the intricate connection between them and salivary gland physiology remains poorly understood. Methods Fluorescence‐based Ca2+ imaging, RNA sequencing, and mitochondrial activity were used to investigate the effects of
Viktor R. Drel, Manigandan Venkatesan, Rahul S. Jasrotia, Yuyang Sun, Viviane Nascimento da Conceicao, Neelanjan Vishnu, Shankara N. Varadarajan, Venugopal R. Bovilla, Rajender K. Motiani, Shobhan Gaddameedhi, Bibhuti B. Mishra, Muniswamy Madesh, Brij B. Singh   +12 more
wiley   +1 more source

Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide. [PDF]

J Midlife Health
Agrawal PK, Garg R.
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea. [PDF]

Chronic Dis Transl Med
Preshy A, Fernandez CJ, Nedai MH, Pappachan JM.   +3 more
europepmc   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

Arthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen, Sanjaykumar Boddul, Zhaojun Li, Zsolt Kasza, Marlene Schülein, Bruno Raposo, Karine Chemin, Per‐Johan Jakobsson, Alexander Espinosa, Lars Klareskog, Fredrik Wermeling   +10 more
wiley   +1 more source

Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence. [PDF]

Front Pharmacol
Li C, Lin C, Li Z, Lv F, Yang W, Ji L, Cai X.   +6 more
europepmc   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source